OP36 Risankizumab Versus Ustekinumab for the Achievement of Clinical Outcomes and Symptom Improvement in Patients With Moderate To Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial

Abstract Background The efficacy and safety of risankizumab (RZB) and ustekinumab (UST) in patients (pts) with moderate to severe Crohn's disease (CD) refractory to prior anti-tumour necrosis factor (TNF)α therapy were compared in the SEQUENCE head-to-head study. Previously, wk24 CD activity in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2024-01, Vol.18 (Supplement_1), p.i65-i66
Main Authors: Dubinsky, M C, D’Haens, G, Atreya, R, Abraham, B, Armuzzi, A, Arguelles-Arias, F, Lindsay, J O, Patel, K, Neimark, E, Huang, X, Anschutz, T, van Haaren, S, O’Brien, D, Ferrante, M
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The efficacy and safety of risankizumab (RZB) and ustekinumab (UST) in patients (pts) with moderate to severe Crohn's disease (CD) refractory to prior anti-tumour necrosis factor (TNF)α therapy were compared in the SEQUENCE head-to-head study. Previously, wk24 CD activity index (CDAI) clinical remission rates (CDAI
ISSN:1873-9946
1876-4479
DOI:10.1093/ecco-jcc/jjad212.0036